Hypersensitivity Type III Immune Complex

Type III Hypersensitivity is a major mechanism of immune-mediated tissue injury, responsible for a spectrum of diseases from transient drug reactions to chronic autoimmune disorders. Understanding this process is critical because it bridges fundamental immunology with clinical practice, explaining how the body's defense system can mistakenly target its own tissues in organs like the kidneys, skin, and joints. Mastering this concept is essential for diagnosing and managing conditions like lupus and for excelling on exams that probe your ability to link molecular mechanisms to systemic pathology.

The Core Mechanism: From Complexes to Damage

At its heart, Type III Hypersensitivity is a disease of misplacement and overreaction. It begins when soluble immune complexes, which are clusters of antigen bound to antibody, form in the bloodstream. Under normal circumstances, these complexes are efficiently cleared by phagocytic cells in the spleen and liver. The pathology arises when there is an excess of these complexes, often due to persistent infection, autoimmunity, or a large influx of antigen. When the clearance mechanisms are overwhelmed, medium-sized immune complexes circulate and deposit in vulnerable tissues.

The primary sites of deposition are areas of high filtration pressure or turbulent blood flow, which mechanically traps the complexes. These include the walls of small blood vessels, the filtering glomeruli of the kidneys, the synovial membranes of joints, and the choroid plexus in the brain. Once deposited, the complexes are not inert. The constant region (Fc) of the antibody within the complex activates the complement system, a cascade of plasma proteins. This activation generates potent pro-inflammatory fragments, notably C5a and C3a, which are anaphylatoxins.

The Inflammatory Cascade and Tissue Injury

The anaphylatoxins C5a and C3a are the critical recruiters of the cellular damage phase. They act as powerful chemotactic signals, drawing neutrophils to the site of immune complex deposition. Neutrophils attempt to phagocytose the deposited complexes but often fail because the complexes are enmeshed in the basement membrane of blood vessels or tissues. Frustrated, the neutrophils degranulate, releasing a barrage of destructive enzymes—including collagenase, elastase, and proteases—directly into the tissue.

Furthermore, the activation of complement leads to the formation of the Membrane Attack Complex (MAC or C5b-9), which can insert into the membranes of nearby host cells, causing lysis. The combined assault of neutrophil enzymes and complement fragments leads to fibrinoid necrosis, a classic histologic finding where vessel walls appear smudgy and pink from the accumulation of immune proteins, fibrin, and cellular debris. This necrotizing vasculitis is the hallmark tissue injury of Type III reactions, compromising blood flow and causing ischemia in the supplied tissue.

Clinical Manifestations and Key Diseases

The clinical picture depends entirely on the organs where the immune complexes deposit. You can diagnose these conditions by connecting the dots between the underlying trigger, the mechanism, and the target organ damage.

Systemic Lupus Erythematosus (SLE) is the classic autoimmune example. Here, autoantibodies are directed against ubiquitous self-antigens like nuclear components (anti-dsDNA). The resulting immune complexes deposit widely, causing a predictable triad: glomerulonephritis (kidney), arthritis (joints), and vasculitic skin rashes. Kidney involvement, or lupus nephritis, is a major cause of morbidity and is directly driven by complex deposition in the glomerular basement membrane.

Serum Sickness is a systemic, transient model of Type III hypersensitivity. Historically, it occurred after administration of animal-derived antisera (e.g., for snake bites); today, it's more commonly seen as a reaction to drugs like penicillin or monoclonal antibodies. The introduced foreign proteins act as antigens, inducing an antibody response. As antibodies form and bind to the circulating antigen, complexes deposit, causing fever, urticaria, arthralgias, lymphadenopathy, and proteinuria. Symptoms resolve as the antigen is cleared.

Other important diseases include Post-streptococcal Glomerulonephritis, where complexes of streptococcal antigen and antibody deposit in the kidneys weeks after a throat or skin infection, and Polyarteritis Nodosa, often associated with Hepatitis B antigen-antibody complexes causing necrotizing inflammation of medium-sized arteries.

The Arthus Reaction: A Localized Model

The Arthus reaction is a localized, experimental, and clinical manifestation of Type III hypersensitivity. It occurs when an individual with pre-existing high levels of circulating IgG antibodies receives an intradermal or subcutaneous injection of the corresponding antigen. The antigen diffuses into the vessel walls where it meets circulating antibodies, forming immune complexes in situ right at the injection site. This triggers the same complement-neutrophil cascade, resulting in localized edema, hemorrhage, and necrosis typically peaking within 4–12 hours. This reaction is distinct from a delayed-type (Type IV) hypersensitivity, which takes 48-72 hours to develop.

Common Pitfalls

Confusing Type II and Type III Hypersensitivity. This is a frequent exam trap. Remember: Type II involves antibodies (IgG/IgM) binding directly to antigens fixed on the surface of a cell or tissue (e.g., in Goodpasture syndrome, antibodies bind directly to basement membrane). Type III involves antibodies binding to soluble antigens, forming circulating complexes that secondarily deposit in tissues. The target is indirect.

Mistaking the Arthus reaction for a delayed hypersensitivity test. A patient developing redness, swelling, and pain at an injection site within hours is showing an Arthus (Type III) reaction. A tuberculin skin test (PPD) that becomes indurated after 48-72 hours is a classic Type IV cell-mediated response. Timing and mechanism are key differentiators.

Overlooking the role of complement. It's not just the complexes themselves that cause damage; it's the complement system they activate. Focusing solely on the complexes without detailing the cascade of C5a, neutrophil recruitment, and MAC formation misses the core pathophysiology of the tissue injury.

Assuming all immune complex diseases are autoimmune. While autoimmune diseases like SLE are prime examples, infections (post-streptococcal GN, viral hepatitis) and exogenous exposures (serum sickness, hypersensitivity pneumonitis) are equally important triggers. Always consider the source of the antigen.

Summary

• Type III Hypersensitivity is driven by the tissue deposition of soluble immune complexes (antigen-antibody), which activate complement and recruit neutrophils, causing inflammatory damage.
• The hallmark histologic lesion is necrotizing vasculitis with fibrinoid necrosis, commonly affecting blood vessel walls, renal glomeruli, joints, and skin.
• Key systemic diseases include Systemic Lupus Erythematosus (anti-nuclear antibodies), Serum Sickness (drug or foreign protein reaction), and Post-streptococcal Glomerulonephritis.
• The Arthus reaction is a localized, rapid-onset (hours) form of Type III hypersensitivity occurring at injection sites in sensitized individuals.
• For exams, critically distinguish Type III (soluble complexes deposit) from Type II (antibody vs. fixed cellular antigen) and remember that complement activation (C5a, MAC) is the non-negotiable link between complex deposition and tissue injury.